AC Immune SA (ACIU)
3.21
-0.20
(-5.87%)
USD |
NASDAQ |
May 17, 16:00
3.21
0.00 (0.00%)
Pre-Market: 20:00
AC Immune Cash from Financing (TTM): 47.53M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 47.53M |
December 31, 2023 | 48.17M |
September 30, 2023 | 2.342M |
June 30, 2023 | 1.654M |
March 31, 2023 | -0.5719M |
December 31, 2022 | -1.411M |
September 30, 2022 | 30.26M |
June 30, 2022 | 35.05M |
March 31, 2022 | 35.07M |
December 31, 2021 | 44.58M |
September 30, 2021 | 12.60M |
June 30, 2021 | 8.084M |
March 31, 2021 | 8.051M |
December 31, 2020 | -0.8565M |
September 30, 2020 | -0.7966M |
June 30, 2020 | -0.1513M |
March 31, 2020 | -0.8754M |
Date | Value |
---|---|
December 31, 2019 | 49.94M |
September 30, 2019 | 50.50M |
June 30, 2019 | 161.26M |
March 31, 2019 | 162.24M |
December 31, 2018 | 111.81M |
September 30, 2018 | 111.80M |
June 30, 2018 | 0.3279M |
March 31, 2018 | 0.2473M |
December 31, 2017 | 0.2751M |
September 30, 2017 | -3.153M |
June 30, 2017 | 66.52M |
March 31, 2017 | 80.39M |
December 31, 2016 | 79.98M |
September 30, 2016 | 112.11M |
June 30, 2016 | 42.41M |
March 31, 2016 | 28.48M |
December 31, 2015 | 28.87M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.411M
Minimum
Dec 2022
161.26M
Maximum
Jun 2019
26.52M
Average
10.34M
Median
Cash from Financing (TTM) Benchmarks
CRISPR Therapeutics AG | 363.19M |
Addex Therapeutics Ltd | 5.863M |
NLS Pharmaceutics Ltd | 1.634M |
Molecular Partners AG | -1.300M |
MoonLake Immunotherapeutics | 530.68M |